Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

doi:10.1016/j.jtho.2016.05.009

Article

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2016

Waqar Saiama N, Bonomi Philip D, Govindan Ramaswamy, Hirsch Fred R, Riely Gregory J, Papadimitrakopoulou Vassiliki, Kazandjian Dickran, Khozin Sean, Larkins Erin, Dickson Dane J, Malik Shakun, Horn Leora, Ferris Andrea, Shaw Alice T, Jänne Pasi A, Mok Tony S K, Herbst Roy, Keegan Patricia, Pazdur Richard, Blumenthal Gideon M

Abstract excerpt

Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Share to Drug Discovery

Share to ErbB Receptors

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Research Design

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.PMID 27401214Read

Biologic approaches to drug selection and targeted therapy: hype or clinical reality?Semantic proximity Read

Pharmacodynamic biomarkers: falling short of the mark?Semantic proximity Read

Targeted therapies in lung cancer.Semantic proximity Read

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.Semantic proximity Read

Current readings: Window-of-opportunity trials for thoracic malignancies.Semantic proximity Read

Putting lung cancer clinical trials into perspective.Semantic proximity Read

Lung cancer. Dacomitinib: getting on target after negative ARCHER trial.Semantic proximity Read

Molecular modalities in the treatment of lung cancer.Semantic proximity Read